News
Medigene reveals pivotal blood cancer therapy data
Medigene – a company concentrating on the development of T cell immunotherapies for solid tumours – has announced final phase 1 dose-escalation results from the study of its MDG1011 candidate.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Medigene – a company concentrating on the development of T cell immunotherapies for solid tumours – has announced final phase 1 dose-escalation results from the study of its MDG1011 candidate.